← Leaderboards
Carol A Paronis
Mc Lean Hospital (Belmont, Ma)
$5,694,850
Attributed
$6,919,202
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $862.8K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,919,202 · 6
By mechanism
R01$5,047,169 · 3
T32$1,229,796 · 1
R21$431,537 · 1
R29$210,700 · 1
Top collaborators
- Raymond G Booth4 shared
- Alexandros Makriyannis4 shared
- Jack Bergman3 shared
Most similar at Mc Lean Hospital (Belmont, Ma)
Same institution · by research overlap
- Elena H Chartoff$4,483,034
- Sidney S Negus$13,528,377
- Jack Bergman$14,885,552
- Roger D. Weiss$29,049,094
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsBehaviorBehavioralAgonistReportingProceduresNovel TherapeuticsAcuteProgramsBasePhysiologicalSelf AdministrationReceptorMonkeysOpioid AgonistIn VivoNonhuman PrimateExperimental StudyCharacteristicsPharmacologyAnimalsDependenceModificationLigands
Grant awards (21)
Training Program on Development of Medications for Substance Use Disorder$347,268
T32 · FY2025 · DA
Training Program on Development of Medications for Substance Use Disorder$224,689
T32 · FY2024 · DA
Training Program on Development of Medications for Substance Use Disorder$339,036
T32 · FY2023 · DA
Behavioral Pharmacology of Synthetic Cannabinoids$525,025
R01 · FY2022 · DA · contact PI
Training Program on Development of Medications for Substance Use Disorder$318,803
T32 · FY2022 · DA
Behavioral Pharmacology of Synthetic Cannabinoids$523,082
R01 · FY2021 · DA · contact PI
In vivo characterization of opioid biased agonists$245,568
R01 · FY2021 · DA · contact PI
Behavioral Pharmacology of Synthetic Cannabinoids$498,848
R01 · FY2020 · DA · contact PI
In vivo characterization of opioid biased agonists$245,568
R01 · FY2020 · DA · contact PI
Behavioral Pharmacology of Synthetic Cannabinoids$544,990
R01 · FY2019 · DA · contact PI
In vivo characterization of opioid biased agonists$317,840
R01 · FY2019 · DA · contact PI
Behavioral Pharmacology of Synthetic Cannabinoids$583,294
R01 · FY2018 · DA · contact PI
Cannabinoid Dependence Resubmission$194,537
R21 · FY2015 · DA · contact PI
Cannabinoid Dependence Resubmission$237,000
R21 · FY2014 · DA · contact PI
Opioids: Relative Reinforcing Strength and Dependence$299,207
R01 · FY2008 · DA · contact PI
Opioids: Relative Reinforcing Strength and Dependence$305,314
R01 · FY2007 · DA · contact PI
Opioids:Relative Reinforcing Strength and Dependence$314,433
R01 · FY2006 · DA · contact PI
Opioids:Relative Reinforcing Strength and Dependence$322,000
R01 · FY2005 · DA
Opioids: Relative Reinforcing Strength and Dependence$322,000
R01 · FY2004 · DA
GABA-ERGIC DRUGS--BEHAVIORAL AND ABUSE RELATED EFFECTS$105,350
R29 · FY2001 · DA
GABA-ERGIC DRUGS--BEHAVIORAL AND ABUSE RELATED EFFECTS$105,350
R29 · FY2000 · DA